Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment

Massimiliano Castellazzi, Serena Delbue, Francesca Elia, Matteo Gastaldi, Diego Franciotta, Roberta Rizzo, Tiziana Bellini, Roberto Bergamaschi, Enrico Granieri, Enrico Fainardi

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds